Who is sponsoring NCT04967625?

NCT04967625 is sponsored by Zhejiang Cancer Hospital.

What drugs are being tested in NCT04967625?

Interventions in NCT04967625: Sintilimab, Anlotinib hydrochloride.

What condition does NCT04967625 study?

NCT04967625 studies Small Cell Lung Cancer Extensive Stage.

Is NCT04967625 still recruiting?

NCT04967625 is currently status unknown. Last updated 28 July 2021.

Last reviewed 2021-07-28 · How we verify

NCT04967625

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC

Status unknown Phase 2 Last updated 28 July 2021

What this trial tests

Phase 2 trial testing Sintilimab in Small Cell Lung Cancer Extensive Stage in 23 participants. Status unknown.

Timeline

26 July 2021

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	Zhejiang Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	26 July 2021
Primary completion	31 December 2022
Estimated completion	31 December 2023

Drugs / interventions tested

Sintilimab — full drug profile →
Anlotinib hydrochloride

Conditions studied

Small Cell Lung Cancer Extensive Stage — all drugs for Small Cell Lung Cancer Extensive Stage →

Sponsor

Zhejiang Cancer Hospital

Who can join

18 and older, any sex, with Small Cell Lung Cancer Extensive Stage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage disease small-cell lung cancer to evaluate the efficacy and safety. 23 patients are expected to be enrolled in this study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies.
Cani M, Napoli VM, Garbo E, Ferrari G, et al · · 2023 · cited 11× · PMID 37240229 · DOI 10.3390/ijms24108883

Verify or expand the search:

Other trials of Sintilimab

Trials testing the same drug.

NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07515625 — Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesop · Phase 2 · not yet recruiting

Other recruiting trials for Small Cell Lung Cancer Extensive Stage

Currently open trials in the same condition.

NCT07227597 — A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6 · Phase 1, PHASE2 · recruiting
NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06348797 — Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC · Phase 1 · recruiting
NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
NCT06429696 — PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer · Phase 2 · recruiting

Other Zhejiang Cancer Hospital trials

Trials by the same sponsor.

NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04967625 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
Last refreshed: 28 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04967625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing